| | |
Page
|
| |||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | | | S-26 | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 2 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 10 | | | |
| | | | 17 | | | |
| | | | 19 | | | |
| | | | 21 | | | |
| | | | 24 | | | |
| | | | 24 | | |
|
Public offering price per share
|
| | | | | | | | | $ | | | |
|
Net tangible book value per share as of June 30, 2021
|
| | | $ | 3.11 | | | | | | | | |
|
Increase in net tangible book value per share attributable to investors purchasing
our common stock and pre-funded warrants in this offering and the concurrent registered direct offering |
| | | | | | | | | | | | |
|
As adjusted net tangible book value per share after this offering and the concurrent
registered direct offering |
| | | | | | | | | | | | |
|
Dilution per share to investors purchasing our common stock and pre-funded warrants in this offering and the concurrent registered direct offering
|
| | | | | | | | | $ | | | |
Underwriter
|
| |
Number of
Shares of common stock |
| |
Number of
Pre-funded Warrants |
|
Oppenheimer & Co. Inc. | | | | | | ||
| | | | | | ||
| | | | | | ||
Total | | | | | |
| | |
Per
Share of common stock |
| |
Per Pre-Funded
Warrant |
| |
Total Without
Exercise of Underwriters’ Option |
| |
Total With Full
Exercise of Underwriters’ Option |
| ||||||||||||
Public offering price
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
Underwriting discounts and commissions(1)
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Proceeds, before expenses, to us
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 2 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 10 | | | |
| | | | 17 | | | |
| | | | 19 | | | |
| | | | 21 | | | |
| | | | 24 | | | |
| | | | 24 | | |